Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis c Clear all

Conditions: Hiv, Hepatitis C
Interventions: Persuasive Health Communication Intervention; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hepatitis C, HIV Infection
Interventions: ABC/Gen-Probe/Chiron HIV-1/HCV 001; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 892 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hepatitis C
Interventions: Research transitional care coordination; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C Virus, HCV Infection, Chronic HCV, Hepatitis C
Interventions: Naringenin; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C, Chronic
Interventions: peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 38
States / cities: Birmingham, Alabama • La Jolla, California • Lancaster, California + 32 more

Conditions: HCV Infection
Interventions: ABT-450, ritonavir, Placebo for ABT-450, Placebo for ritonavir; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Hepatitis C
Interventions: Not listed
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection, HIV (Human Immunodeficiency Virus)
Interventions: Physician-Initiated Screening (Conventional Screening), FOCUS (Universal Screening), HepC-EnD (Targeted Screening); Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 79 Years
Enrollment: 6,466 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Renal Failure Chronic, Hepatitis C
Interventions: Zepatier, Zepatier plus Sofosbuvir; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C, HIV Infections
Interventions: Double dose pegylated interferon with weight based Ribavirin, standard dose pegylated interferon alfa -2a and ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis, Cirrhosis, Fatty Liver, Obesity, Childhood, Bariatric Surgery Candidate
Interventions: Not listed
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 7 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2099
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Intravenous Drug Usage, HIV/AIDS
Interventions: Integrated care van (ICV); Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C, Chronic
Interventions: midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more

Conditions: Substance Abuse
Interventions: Strengths-based case management, Case management plus facilitated treatment alliance; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 726 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hepatitis C
Interventions: CTS-1027, pegylated interferon, Ribavirin, Placebo; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 45
States / cities: Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 3 more

Conditions: Hepatitis C
Interventions: Hepatitis C Educational Brochure, Hepatitis C Educational Video; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Buffalo, New York • Orchard Park, New York

Conditions: HCV
Interventions: Not listed
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 19 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: Chronic Hepatitis C
Interventions: Pioglitazone (Actos); Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C Virus Infection
Interventions: Daclatasvir, Asunaprevir, Pegylated interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 20
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 17 more

Conditions: Hepatitis C, Chronic, Substance Use Disorders
Interventions: Peer specialist (PS), Incentives, telehealth visits, phone access; Behavioral
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Hepatitis C
Interventions: SOF/VEL/VOX, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 47
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more

Conditions: HCV
Interventions: Prophylaxis (P2W), Transmit and Treat (T&T); Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: La Jolla, California • Loma Linda, California • Baltimore, Maryland + 5 more

Search by objective public record fields.

Development and Pilot Testing of a PHCI for Emergency Department Patients Who Decline Rapid HIV/ HCV Screening

Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV

Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants

Implementation and Evaluation of Care Coordination in Linkage to Care for Hepatitis C Following Release From New York City Jails

A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

Characterization of Clonal B Cell Populations in HCV Infection

Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients

Blood Collection Biorepository for Liver Disease Research

Building on Needle Exchange to Optimize Prevention & Treatment

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Intervention to Reduce Injection Drug Use

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting

Hepatitis C-Video vs. Brochure Education Delivery

Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects

Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Linkage to Care for Persons With Hep C Infection

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients